RSS Feeds
Leukopenia and Thrombocytopenia Caused by Thiazolidinediones
- Colleen Digman, MD;
- Andreas K. Klein, MD; and
- Anastassios G. Pittas, MD
- From Tufts-New England Medical Center, Boston, MA 02111.
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
TO THE EDITOR:
Background: Thiazolidinediones are orally administered drugs used to control hyperglycemia in patients with type 2 diabetes mellitus (1). Although mild dilutional anemia is often seen with thiazolidinedione therapy, no adverse effects of thiazolidinedione on leukocytes or platelets have been described.
Objective: To report the first case, to our knowledge, of a patient who developed leukopenia and …
